林首恒 副研究员 博士 广东省 研究领域: 生物医药 研究方向: 1.肺癌转移的机制; 2.靶向肿瘤微环境的免疫治疗。 所在单位: 中国科学院广州生物医药与健康研究院

基本信息

所在单位:
中国科学院广州生物医药与健康研究院
单位类型:
科研机构
职务:
副研究员
职称:
副研究员
最高学历:
博士
教育经历:
2013.09-2018.07 中国科学院大学 博士
2009.09-2013.07 华南农业大学 学士
工作经历:
2021.03至今 中国科学院广州生物医药与健康研究院 副研究员
2018.08-2021.02 广州医科大学附属第三医院 博士后
专家荣誉:
广东省科技进步二等奖 “人源化小鼠及其临床前评估平台的建立及应用“(2019, 7/10)

科研能力

研究领域:
生物医药
研究方向:
1.肺癌转移的机制;
2.靶向肿瘤微环境的免疫治疗。
论文著作:
1. Lin, Shouheng#; Zhang, Xuchao#; Huang, Guohua#; Cheng, Lin#; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Li, Baiheng; Wei, Wei; Liu, Pentao; Pei, Duanqing; Li, Yangqiu; Wen, Zhesheng; Cui, Shuzhong; Li, Peng; Sun, Xiaofang*; Wu, Yilong*; Yao, Yao*; Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cell,Oncogene,2021 Feb;40(8):1476-1489.
2. Lin, Shouheng; Cheng, Lin; Ye, Wei; Li, Shanglin; Zheng, Diwei; Qin, Le; Wu, Qiting; Long, Youguo; Lin, Simiao; Wang, Suna; Huang, Guohua; Li, Peng; Yao, Yao*; Sun, Xiaofang*; Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies, Frontiers in Immunology, 2021 Apr 2;12:642528.
3. Lin, Shouheng#; Huang, Guohua#; Cheng, Lin#; Li, Zhen; Xiao, Yiren; Deng, Qiuhua; Jiang, Yuchuan; Li, Baiheng; Lin, Simiao; Wang, Suna; Wu, Qiting; Yao, Huihui; Cao, Su; Li, Yang; Liu, Pentao; Wei, Wei; Pei, Duanqing; Yao, Yao; Wen, Zhesheng; Zhang, Xuchao; Wu, Yilong; Zhang, Zhenfeng; Cui, Shuzhong; Sun, Xiaofang; Qian, Xueming*; Li, Peng*; Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy, mAbs, 2018, 10(8): 1301-1311.
4. Lin, Shouheng#; Huang, Guohua#; Xiao, Yiren; Sun, Wei; Jiang, Yuchuan; Deng, Qiuhua; Peng, Muyun; Wei, Xinru; Ye, Wei; Li, Baiheng; Lin, Simiao; Wang, Suna; Wu, Qiting; Liang, Qiubin; Li, Yangqiu; Zhang, Xuchao; Wu, Yilong; Liu, Pentao; Pei, Duanqing; Yu, Fenglei; Wen, Zhesheng; Yao, Yao; Wu, Donghai*; Li, Peng*; CD215 Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression, Frontiers in Immunology, 2017, 8: 1713.
5. Lai, Yunxin; Wei, Xinru; Lin, Shouheng; Qin, Le; Cheng, Lin; Li, Peng*; Current status and perspectives of patient-derived xenograft models in cancer research, Journal of Hematology & Oncology, 2017, 10(1): 106.
6. Xiong, Zeyu; Xie, Yingjun; Yang, Yi; Xue, Yanting; Wang, Ding; Lin, Shouheng; Chen, Diyu; Lu, Dian; He, Lina; Song, Bing; Yang, Yinghong; Sun, Xiaofang*;Efficient gene correction of an aberrant splice site in beta-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides,Journal of Cellular and Molecular Medicine, 2019, 23(12): 8046-8057.
7.Chang, Yanqun; Lin, Shouheng; Li, Yongsheng*; Liu, Song; Ma, Tianbao; Wei, Wei; Umbilical cord blood CD34(+) cells administration improved neurobehavioral status and alleviated brain injury in a mouse model of cerebral palsy,Childs Nerv Syst, 2021, 37(7): 2197-2205.
8.Jiang, Zhiwu; Wu, Di; Lin, Shouheng; Li, Peng*; CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia,Biomark Res, 2016, 4: 23.
9. Lin, Shouheng; Zhao, Ruocong; Xiao, Yiren; Li, Peng*;Mechanisms determining the fate of hematopoietic stem cells,Stem Cell Investig, 2015, 2: 10.
科研项目:
1. 国家自然科学基金青年项目,82003054,MDSC-肿瘤细胞正向反馈促进非小细胞肺癌转移的机制研究,2021.1-2023-12,项目负责人。
2. 广东省基础与应用基础研究基金项目,2019A1515110084,MDSC来源的CCL11促进NSCLC的间充质样转变和转移的机制研究,2020.1-2021.12,项目负责人。
3. 第64批中国博士后科学基金面上资助,2018M640771,地贫小鼠模型的建立及基因编辑治疗地贫的临床前评估,2018.11-2021.2,项目负责人。
在线客服 在线留言 小程序 公众号 4001789689 <<显示